Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| N01CM62201 | U.S. NIH Grant/Contract | View source | |
| CDR0000538086 | Registry Identifier | PDQ (Physician Data Query) | |
| 14954A |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This randomized phase II trial is studying how well pazopanib hydrochloride works after leuprolide or goserelin in treating patients with relapsed prostate cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate or goserelin acetate, may lessen the amount of androgens made by the body. Giving pazopanib after leuprolide or goserelin may be an effective treatment for prostate cancer
PRIMARY OBJECTIVES:
I. Determine if pazopanib hydrochloride is able to increase time to progression, as measured by prostate-specific antigen (PSA), after 6 months of limited gonadotropin-releasing hormone (GnRH) agonist therapy comprising leuprolide acetate or goserelin in patients with androgen-sensitive relapsed stage D0 prostate cancer.
SECONDARY OBJECTIVES:
I. Determine the adverse events in patients treated with this regimen. II. To monitor for changes in testosterone in relationship to pazopanib therapy versus observation.
OUTLINE:
Patients receive androgen blockade comprising GnRH agonist therapy (e.g., leuprolide acetate or goserelin acetate) for 6 months. Patients who develop metastases or have PSA progression while on GnRH agonist therapy are removed from the study and placed on total androgen blockade. The remaining patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients undergo observation.
After completion of study treatment, patients are followed up periodically for up to 12 months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pazopanib | Experimental | Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. |
|
| Observation | Active Comparator | Patients undergo observation after treatment with leuprolide acetate and goserelin acetate. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| pazopanib hydrochloride | Drug | Given PO |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Median Time to PSA Progression | The median time to disease progression for the therapy and observation groups will be estimated using the Kaplan-Meier estimate and compared using the log-rank test. | Baseline, every 4 weeks during treatment, and up to 12 months after completion of study treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Median PSA Progression-free Survival | Kaplan-Meier estimates for PSA progression-free survival will be computed for the pazopanib and active surveillance groups and compared using the log rank test. The outcome measure is median PSA progression-free survival time. | Time from randomization to PSA progression or death from any cause |
Not provided
Inclusion Criteria:
Histologically or cytologically confirmed prostate cancer
Must have undergone some definitive local therapy for prostate cancer
Must be free of macrometastatic disease, as evidenced by computed tomography (CT) scan and bone scan, if serum PSA ≥ 10 ng/mL prior to GnRH agonist therapy
Progressive disease meeting the following criteria: NOTE: Patients who have undergone a prostatectomy and have two detectable, rising serum PSA levels are eligible
PSA < 0.5 ng/mL
Testosterone < 30 ng/mL
No measurable disease
No brain metastases requiring steroid or anticonvulsant therapy
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 60- 100%
Prothrombin time (PT)/international normalization ratio (INR)/partial thromboplastin time (PTT) ≤ 1.2 times upper limit of normal (ULN)
Bilirubin normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN
Creatinine ≤ 1.5 times ULN OR creatinine clearance > 50 mL/min
Proteinuria ≤ 1+ on 2 consecutive dipsticks > 1 week apart
Urine protein: creatinine ratio < 1 OR urine protein < 1.0 g/24 hours
Fertile patients must use effective double-barrier contraception during study therapy OR completely abstain from sexual intercourse 14 days prior to, during, and for ≥ 21 days after completion of study therapy
No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or to other agents used in the study
No concurrent uncontrolled illness including, but not limited to, any of the following:
No human immunodeficiency virus (HIV) positivity
No condition that impairs the ability to swallow and retain pazopanib hydrochloride tablets, including any of the following:
No other conditions, including any of the following:
Serious or nonhealing wound, ulcer, or bone fracture
Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
Cerebrovascular accident within the past 6 months
Myocardial infarction, admission for unstable angina, cardiac angioplasty, or stenting within the past 6 months
Venous thrombosis within the past 12 weeks
New York Heart Association (NYHA) class III or IV heart failure
Systolic blood pressure (BP) ≤ 140 mm Hg and diastolic BP ≤ 90 mm Hg
More than 3 months since prior antiandrogen
More than 4 months since prior orchiectomy or implantable luteinizing LHRH agonist
No prior GnRH agonists except for neoadjuvant or adjuvant therapy associated with local therapy
Patients who have started a GnRH agonist for micrometastatic disease after local therapy allowed provided the following criteria are met:
No prior or concurrent GnRH antagonist therapy
No concurrent ketoconazole
No concurrent cytochrome P450 2C9 (CYP2C9) substrates, including any of the following:
Anticoagulants (e.g., warfarin [therapeutic doses only])
Oral hypoglycemics (e.g., glipizide, glyburide, tolbutamide, glimepiride, or nateglinide)
Ergot derivatives (e.g., dihydroergotamine, ergonovine, ergotamine, or methylergonovine)
Neuroleptics (e.g., pimozide)
Erectile dysfunction agents (e.g., sildenafil, tadalafil, or vardenafil)
Antiarrhythmics (e.g., bepridil, flecainide, lidocaine, mexiletin, amiodarone, quinidine, or propafenone)
Immune modulators (e.g., cyclosporine, tacrolimus, or sirolimus)
Miscellaneous medications (e.g., theophylline, quetiapine, risperidone, tacrine, clozapine, or atomoxetine)
No concurrent medications associated with the risk of QTc prolongation and/or Torsades de Pointes
No other concurrent non-Food and Drug Administration (FDA)-approved agents
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Edwin Posadas | University of Chicago Comprehensive Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637-1470 | United States | ||
| University of Wisconsin Hospital and Clinics |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22006050 | Result | Ward JE, Karrison T, Chatta G, Hussain M, Shevrin D, Szmulewitz RZ, O'Donnell PH, Stadler WM, Posadas EM. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar;15(1):87-92. doi: 10.1038/pcan.2011.49. Epub 2011 Oct 18. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Pazopanib, Leuprolide Acetate, and Goserelin Acetate | Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. pazopanib hydrochloride: Given PO leuprolide acetate goserelin acetate |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| leuprolide acetate | Drug |
|
|
| goserelin acetate | Drug |
|
|
| Madison |
| Wisconsin |
| 53792 |
| United States |
| FG001 |
| Leuprolide Acetate and Goserelin Acetate Only |
Patients undergo observation after treatment with leuprolide acetate and goserelin acetate. leuprolide acetate goserelin acetate |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Baseline demographics data for this multi-center trial are only available for participants at The University of Chicago with known study arm assignment.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Pazopanib, Leuprolide Acetate, and Goserelin Acetate | Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. pazopanib hydrochloride: Given PO leuprolide acetate goserelin acetate |
| BG001 | Leuprolide Acetate and Goserelin Acetate Only | Patients undergo observation after treatment with leuprolide acetate and goserelin acetate. leuprolide acetate goserelin acetate |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median | Full Range | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Median Time to PSA Progression | The median time to disease progression for the therapy and observation groups will be estimated using the Kaplan-Meier estimate and compared using the log-rank test. | Patients were taken off study early, so many survival times were censored. At no point during the study did the proportion of subjects who progressed drop to 50%. Thus, it was not possible to calculate median time to disease progression. | Posted | Baseline, every 4 weeks during treatment, and up to 12 months after completion of study treatment |
|
| ||||||||||||||||||||||
| Secondary | Median PSA Progression-free Survival | Kaplan-Meier estimates for PSA progression-free survival will be computed for the pazopanib and active surveillance groups and compared using the log rank test. The outcome measure is median PSA progression-free survival time. | Patients were taken off study early, so many survival times were censored. At no point during the study did the proportion of subjects who progressed drop to 50%. Thus, it was not possible to calculate median time to PSA progression. | Posted | Time from randomization to PSA progression or death from any cause |
|
|
1 year
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Pazopanib, Leuprolide Acetate, and Goserelin Acetate | Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. pazopanib hydrochloride: Given PO leuprolide acetate goserelin acetate | 5 | 18 | 16 | 18 | ||
| EG001 | Leuprolide Acetate and Goserelin Acetate Only | Patients undergo observation after treatment with leuprolide acetate and goserelin acetate. leuprolide acetate goserelin acetate | 0 | 19 | 2 | 19 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Alanine aminotransferase increased | Investigations | CTCAE v 4.0 | Non-systematic Assessment |
| |
| Hypertension | Vascular disorders | CTCAE v 4.0 | Non-systematic Assessment |
| |
| Chest pain - cardiac | Cardiac disorders | CTCAE v 4.0 | Non-systematic Assessment |
| |
| Thromboembolic event | Vascular disorders | CTCAE v 4.0 | Non-systematic Assessment |
| |
| Dizziness | Nervous system disorders | CTCAE v 4.0 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by an reduction in the amount of hemoglobin in 100 ml of blood. |
|
| Tinnitus | Ear and labyrinth disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by noise in the ears, such as ringing, buzzing, roaring or clicking. |
|
| Blurred vision | Eye disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by visual perception of unclear or fuzzy images. |
|
| Eye disorders - Other | Eye disorders | CTCAE 4.0 | Non-systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a sensation of marked discomfort in the abdominal region. |
|
| Constipation | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by irregular and infrequent or difficult evacuation of the bowels. |
|
| Diarrhea | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by frequent and watery bowel movements. |
|
| Dyspepsia | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by an uncomfortable, often painful feeling in the stomach, resulting from impaired digestion. Symptoms include burning stomach, bloating, heartburn, nausea and vomiting. |
|
| Esophagitis | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by inflammation of the esophageal wall. |
|
| Flatulence | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a state of excessive gas in the alimentary canal. |
|
| Gastrointestinal disorders - Other | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment |
| |
| Hemorrhoids | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by the presence of dilated veins in the rectum and surrounding area. |
|
| Mucositis oral | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by inflammation of the oral mucosal. |
|
| Nausea | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a queasy sensation and/or the urge to vomit. |
|
| Oral pain | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a sensation of marked discomfort in the mouth, tongue or lips. |
|
| Stomach pain | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a sensation of marked discomfort in the stomach. |
|
| Vomiting | Gastrointestinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by the reflexive act of ejecting the contents of the stomach through the mouth. |
|
| Edema face | General disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by swelling due to excessive fluid accumulation in facial tissues. |
|
| Fatigue | General disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities. |
|
| Pain | General disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by the sensation of marked discomfort, distress or agony. |
|
| Alanine aminotransferase increased | Investigations | CTCAE 4.0 | Non-systematic Assessment | A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen. |
|
| Alkaline phosphatase increased | Investigations | CTCAE 4.0 | Non-systematic Assessment | A finding based on laboratory test results that indicate an increase in the level of alkaline phosphatase in a blood specimen. |
|
| Aspartate aminotransferase increased | Investigations | CTCAE 4.0 | Non-systematic Assessment | A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen. |
|
| Blood bilirubin increased | Investigations | CTCAE 4.0 | Non-systematic Assessment | A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice. |
|
| Creatinine increased | Investigations | CTCAE 4.0 | Non-systematic Assessment | A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen. |
|
| Lymphocyte count decreased | Investigations | CTCAE 4.0 | Non-systematic Assessment | A finding based on laboratory test results that indicate a decrease in number of lymphocytes in a blood specimen. |
|
| Platelet count decreased | Investigations | CTCAE 4.0 | Non-systematic Assessment | A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen. |
|
| Weight gain | Investigations | CTCAE 4.0 | Non-systematic Assessment | A finding characterized by an increase in overall body weight; for pediatrics, greater than the baseline growth curve. |
|
| Weight loss | Investigations | CTCAE 4.0 | Non-systematic Assessment | A finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve. |
|
| White blood cell decreased | Investigations | CTCAE 4.0 | Non-systematic Assessment | A finding based on laboratory test results that indicate an decrease in number of white blood cells in a blood specimen. |
|
| Anorexia | Metabolism and nutrition disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a loss of appetite. |
|
| Hyperglycemia | Metabolism and nutrition disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance. |
|
| Hyperkalemia | Metabolism and nutrition disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by laboratory test results that indicate an elevation in the concentration of potassium in the blood; associated with kidney failure or sometimes with the use of diuretic drugs. |
|
| Hypoalbuminemia | Metabolism and nutrition disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood. |
|
| Hypoglycemia | Metabolism and nutrition disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by laboratory test results that indicate a low concentration of glucose in the blood. |
|
| Hypomagnesemia | Metabolism and nutrition disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the blood. |
|
| Hyponatremia | Metabolism and nutrition disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by laboratory test results that indicate a low concentration of sodium in the blood. |
|
| Hypophosphatemia | Metabolism and nutrition disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood. |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a sensation of marked discomfort in a joint. |
|
| Back pain | Musculoskeletal and connective tissue disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by marked discomfort sensation in the back region. |
|
| Chest wall pain | Musculoskeletal and connective tissue disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by marked discomfort sensation in the chest wall region. |
|
| Musculoskeletal and connective tissue disorder - Other, specify | Musculoskeletal and connective tissue disorders | CTCAE 4.0 | Non-systematic Assessment |
| |
| Dizziness | Nervous system disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a disturbing sensation of lightheadedness, unsteadiness, giddiness, spinning or rocking. |
|
| Dysgeusia | Nervous system disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by abnormal sensual experience with the taste of foodstuffs; it can be related to a decrease in the sense of smell. |
|
| Headache | Nervous system disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve. |
|
| Memory impairment | Nervous system disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a deterioration in memory function. |
|
| Nervous system disorders - Other | Nervous system disorders | CTCAE 4.0 | Non-systematic Assessment |
| |
| Peripheral sensory neuropathy | Nervous system disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by inflammation or degeneration of the peripheral sensory nerves. |
|
| Anxiety | Psychiatric disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus. |
|
| Libido decreased | Psychiatric disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a decrease in sexual desire. |
|
| Proteinuria | Renal and urinary disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin. |
|
| Renal and urinary disorders - Other | Renal and urinary disorders | CTCAE 4.0 | Non-systematic Assessment |
| |
| Urinary frequency | Renal and urinary disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by urination at short intervals. |
|
| Urinary incontinence | Renal and urinary disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by inability to control the flow of urine from the bladder. |
|
| Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by an inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. |
|
| Cough | Respiratory, thoracic and mediastinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by sudden, often repetitive, spasmodic contraction of the thoracic cavity, resulting in violent release of air from the lungs and usually accompanied by a distinctive sound. |
|
| Dyspnea | Respiratory, thoracic and mediastinal disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by an uncomfortable sensation of difficulty breathing. |
|
| Alopecia | Skin and subcutaneous tissue disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a decrease in density of hair compared to normal for a given individual at a given age and body location. |
|
| Photosensitivity | Skin and subcutaneous tissue disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by an increase in sensitivity of the skin to light. |
|
| Pruritus | Skin and subcutaneous tissue disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by an intense itching sensation. |
|
| Skin and subcutaneous tissue disorders - Other | Skin and subcutaneous tissue disorders | CTCAE 4.0 | Non-systematic Assessment |
| |
| Skin ulceration | Skin and subcutaneous tissue disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by circumscribed, inflammatory and necrotic erosive lesion on the skin. |
|
| Hot flashes | Vascular disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by an uncomfortable and temporary sensation of intense body warmth, flushing, sometimes accompanied by sweating upon cooling. |
|
| Hypertension | Vascular disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a pathological increase in blood pressure; a repeatedly elevation in the blood pressure exceeding 140 over 90 mm Hg. |
|
| Hypotension | Vascular disorders | CTCAE 4.0 | Non-systematic Assessment | A disorder characterized by a blood pressure that is below the normal expected for an individual in a given environment. |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Walter M. Stadler, MD | The University of Chicago | (773) 702-6149 | wstadler@medicine.bsd.uchicago.edu |
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C516667 | pazopanib |
| D016729 | Leuprolide |
| D017273 | Goserelin |
| ID | Term |
|---|---|
| D007987 | Gonadotropin-Releasing Hormone |
| D010906 | Pituitary Hormone-Releasing Hormones |
| D007028 | Hypothalamic Hormones |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D009479 | Neuropeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D009842 | Oligopeptides |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |
Not provided
Not provided
| Male |
|
| Participants |
|